|
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM. |
|
|
|
Consulting or Advisory Role - Monteris Medical; Newlink Genetics; ReNeuron |
Research Funding - ZIOPHARM Oncology (Inst) |
Other Relationship - American Physician Institute |
|
|
Stock and Other Ownership Interests - DNAtrix; DNAtrix; DNAtrix; DNAtrix; DNAtrix |
|
Consulting or Advisory Role - Advantagene; Alcyone Lifesciences; DNAtrix; InSightec; NanoTX; Oncorus; Sigilon Therapeutics; StemGen; Tocagen; ZIOPHARM Oncology |
|
Patents, Royalties, Other Intellectual Property - Patents related to oncolytic virus technology, gene therapy, microRNA, exosome, antibodies |
|
|
Travel, Accommodations, Expenses - Optune |
|
|
Employment - ImmunoCellular Therapeutics |
Leadership - ImmunoCellular Therapeutics; Kairos Pharma |
Stock and Other Ownership Interests - ImmunoCellular Therapeutics; Kairos Pharma |
Consulting or Advisory Role - ImmunoCellular Therapeutics |
Patents, Royalties, Other Intellectual Property - ImmunoCellular Therapeutics; Kairos Pharma |
|
|
Employment - Hackensack Meridian Health |
|
|
Stock and Other Ownership Interests - Agios |
Honoraria - Monteris Medical |
Research Funding - Monteris Medical |
|
|
Employment - ZIOPHARM Oncology |
Stock and Other Ownership Interests - ZIOPHARM Oncology |
|
|
Employment - ZIOPHARM Oncology |
Stock and Other Ownership Interests - Alexion Pharmaceuticals; ZIOPHARM Oncology |
Consulting or Advisory Role - Gemini Therapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - ZIOPHARM Oncology |
Stock and Other Ownership Interests - ZIOPHARM Oncology |
|
|
Employment - ZIOPHARM Oncology |
|
|
Employment - ZIOPHARM Oncology |
|
|
|
|
|
Employment - ZIOPHARM Oncology |
Leadership - ZIOPHARM Oncology |
Stock and Other Ownership Interests - Cellchorus; CytoSen; Immatics; Taro; ZIOPHARM Oncology |
Patents, Royalties, Other Intellectual Property - City of Hope; Immatics; MD Anderson Cancer Center; Sangamo Bioscience; ZIOPHARM Oncology |